Joyce Jaio went to her doctor because she could feel kicking in her stomach. Her pregnancy tests had come back negative, so nobody ordered a blood test. She was told it was postpartum depression. She was, in fact, halfway through a pregnancy. “That was when I realised the medical system was broken,” she says.

Dr Ariella Heffernan-Marks heard stories like Joyce’s constantly during her internship at a hospital in Bondi Junction. Young women, frightened of a system that wasn’t listening to them, turning to social media because it felt more reliable than their own doctor. Ariella isn’t just a founder who spotted a gap in the market. She’s a doctor who watched the gap happen, appointment after appointment, then trained in reproductive biology and realised the problem went deeper than any one clinic. The research base itself had been built around male physiology, which meant the tools doctors relied on were working against women by design, not by accident.

That’s the problem Ovum AI exists to solve. It’s why MooCoo Ventures has backed the company’s seed round.

What Ovum does

Think of Ovum as a health diary that talks back. A woman logs her symptoms, her cycle, her sleep, her wearable data, whatever she’s noticed that day, and Ovum builds a picture of her health over time rather than treating each entry as a one-off. The app learns her patterns and flags things worth paying attention to before she even thinks to ask.

The clearest expression of this is the “orb” — one visual that sums up a woman’s health across six factors at a glance. And when it’s time to see a doctor, Ovum turns months of scattered logging into a clean summary a clinician can actually use in a ten-minute consult, instead of a rushed recap that leaves half the story out. It goes one step further, too. Book a telehealth appointment through EverMed, or a prescription through InstantScripts, and it happens without leaving the app.

Why the tech matters

Ovum is building its own AI system for women’s health, not bolting a generic model onto a tracking app. The point of that investment is memory: the longer a woman uses it, the better it understands her. That’s a harder problem than most FemTech apps are trying to solve, and it shows in how seriously Ovum is treating the regulatory side. The company is SOC2 and GDPR compliant. Clinical trials are underway at UNSW, the Royal Hospital for Women and the George Institute for Global Health. And it’s working through Class I medical device approval in New Zealand and Hong Kong.

That’s a slower path than shipping a lifestyle app. It’s also the only path that eventually lets Ovum sit inside a clinician’s workflow, rather than beside it.

The team around her

Ariella isn’t building this alone. Kahlia Grant leads marketing after scaling consumer products at Leonardo AI and Immutable. Alex Buntowe, the founding engineer, spent years building enterprise infrastructure at IBM and Endeavour Group. Noah Keddie runs partnerships off a background in B2B sales at Lendi. And Rachel Delaney, General Counsel, brings health-sector regulatory experience from Telstra Health and Lexer — useful, given the medical device approvals Ovum is chasing. An advisory board of clinicians, reproductive biologists and longevity researchers rounds out the bench, with trial oversight from UNSW, the University of Melbourne and Life Fertility Clinic.

What convinced us

Two things, really. The first is the business model. Ovum AI isn’t relying on consumer subscriptions alone, the way most FemTech apps do. It also sells into insurers, employers and clinics, earns referral fees through its telehealth and prescription integrations, and is building a health dataset that gets more valuable the longer it runs. If the consumer side converts more slowly than hoped, the rest of the business doesn’t stall with it.

The second is that the early numbers back up the story. The company reports 83% first-month retention, against a typical health-app benchmark of 3–12%. Six per cent monthly churn, against a norm of 10–15%. Those aren’t vanity metrics. They’re one of the better signals we have that people are actually getting value from the product, not just downloading it out of curiosity. On the enterprise side, 63 meetings since last July have turned into 27 closed, won or pending contracts, including Medibank Corporate and Australian Red Cross Lifeblood. Real counterparties tend to say more than a slide full of projected demand ever does.

We also paid attention to who else showed up for this round. Admiralty Capital Group led it — its founding partner Amanda Andriano called Ariella “uniquely positioned to lead this movement” — and Giant Leap and Antler, both pre-seed backers, came back to invest again. Investors rarely return to a company unless their first read on the founder held up under closer scrutiny.

The traction, in brief

Seven months after launch, downloads have passed 14,000 and are growing 22% month-on-month. But the number that matters most is this one: the company says users are twice as likely to feel heard by a clinician after using it. The attention has followed the traction, too — coverage from Forbes to the South China Morning Post, and a run of industry awards along the way.

Why now, and why her

Three things are lining up at once. AI has only recently become capable of the kind of proactive, personal health support Ovum is building — this wasn’t possible two years ago. Wearables are everywhere now, generating more personal health data than anyone quite knows what to do with. And governments, insurers and employers are finally paying attention to the gender health gap, which means the policy and commercial tailwinds are real, not theoretical.

None of that matters much without the right founder in the room. Ariella has said it better than we could: “I’ve sat on both sides of the desk, as a patient and as a doctor, and that’s why this mission matters so much to me.” That’s not a line from a pitch deck. It’s the reason the product looks the way it does — built by someone who has needed exactly what she’s now building.

Interested in deals like this?

To explore upcoming opportunities, visit moocoo.vc/investment-opportunities or get in touch.